Merck's new sleep drug clears DEA hurdle; Adcock's turnaround will take awhile, CEO says;

@FiercePharma: Mutated poliovirus found to beat vaccine protection. Article | Follow @FiercePharma

@EricPFierce: CPhI Worldwide will host #CPhIChat to debate the future of pharma for those of you who want a piece of that. Release | Follow @EricPFierce

@CarlyHFierce: ICYMI earlier: Does Pfizer still need AstraZeneca's vaccines business? Story | Follow @CarlyHFierce

> Merck's ($MRK) newly FDA-approved insomnia drug Belsomra (surovexant) won scheduling from the Drug Enforcement Administration, clearing the way for a launch. Report

> South Africa's Adcock Ingram posted a hefty 9-month loss, thanks to writedowns on a turnaround plan and weak demand for its drugs; CEO Kevin Wakeford warned a return to profitability would take time. Report

> TWi Pharmaceuticals said it won final approval for its version of Par Pharmaceuticals' appetite stimulant for AIDS patients, Megace ES. Report

> Johnson & Johnson's ($JNJ) newly honed recruitment strategy has helped the company improve its applicant pool and reduce turnover among new hires. Report

Medical Device News

@FierceMedDev: ReShape targets U.S. approval as EU study shows major weight loss. More | Follow @FierceMedDev

@VarunSaxena2: Between new Brain project initiative and 2 recent $COV buys + $BSX's buy of Bayer's devices, peripheral devices are officially a thing. | Follow @VarunSaxena2

@EmilyWFierce: Covidien snatched up venous disease treatment developer Sapheon for an undisclosed sum. Story | Follow @EmilyWFierce

@MichaelGFierce: Organic nanoparticles offer 'complete package' against cancer: delivery and imaging. Article | Follow @MichaelGFierce

> J&J's DePuy Synthes unit slapped with FDA Class I recall for jaw-stabilizing device. More

> Biomarker could improve early rheumatoid arthritis diagnosis. News

> ReShape targets U.S. approval as EU study shows major weight loss. Story

Biotech News

@FierceBiotech: FDA lifts a hold on one of OncoMed's cancer drug programs. Article | Follow @FierceBiotech

@JohnCFierce: Trending today - What's the #1 biotech hub for VCs? (It's still not Boston). Story | Follow @JohnCFierce

@EmilyMFierce: Canadian Immunovaccine reports positive preclinical data for Ebola vaccine. More | Follow @EmilyMFierce

> Repros gets a lift from a head-to-head testosterone study. More

> PCSK9 race heads to the finish line with Amgen's evolocumab application. Story

> Two new biotech IPOs help set the stage for the fall parade. Article

Vaccines News

> Glaxo's Ebola vaccine trial set to begin in September. Article

> Does Pfizer still need AstraZeneca's vaccines business? Story

> Advaxis teams up with Merck to test its vaccine in prostate cancer. More

> Diamyd diabetes vax, once spurned by J&J, gets an EU boost. Report

> Mutated polio virus found to beat vaccine protection. Story

Pharma Manufacturing News

> NAFTA says FDA was in its rights to ban Apotex plants. More

> Merck KGaA starts work on what will be its second-largest plant. Article

> GSK, NewLink ramp up production of Ebola drugs, even as they conduct trials. Piece

> Patheon gets U.S. biologics plants with Gallus deal. Story

> Novo buys U.S. plant ditched by Olympus. Article

And Finally... Could untreated hot flashes be a drag on the U.S. economy? A new drugmaker-funded study says so. Report

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.